CYP2C19 genotype and outcomes of clopidogrel treatment.

@article{Siasos2011CYP2C19GA,
  title={CYP2C19 genotype and outcomes of clopidogrel treatment.},
  author={Gerasimos Siasos and Dimitris Tousoulis and Christodoulos Stefanadis},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 5},
  pages={481-2}
}
To the Editor: Paré et al. (Oct. 28 issue)1 report that among genotyped patients with acute coronary syndromes or atrial fibrillation, the effects of clopidogrel were consistent irrespective of the loss-of-function CYP2C19*2 allele, whereas gain-offunction CYP2C19*17 carriers with acute coronary syndromes benefited. Unlike these predominantly noninterventionally treated patients, loss-of-function genotypes may play a role in high-risk groups throughout the peri-interventional phase in patients… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Effects of CYP 2 C 19 genotype on outcomes of clopidogrel treatment

G Paré, Mehta, S Yusuf
N Engl J Med • 2010

Genetic variants in ABCB 1 and CYP 2 C 19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITONTIMI 38 trial : a pharmacogenetic analysis

JL Mega, SL Close, SD Wiviott
Lancet • 2010

The role of the cytochrome P450 polymorphism in clopidogrel efficacy and clinical utility

D Tousoulis, G Siasos, M Zaromitidou
Curr Med Chem 2010 December 14 (Epub ahead of print) • 2010

Similar Papers

Loading similar papers…